Interleukin-3 data

By WIR Staff | Dec 13, 1993 | 8:00 AM GMT

A Phase I/II trial of IL-3 and GM-CSF in patients with Hodgkin's disease and in non-Hodgkin's lymphoma undergoing autologous bone marrow transplant (ABMT) showed that sequential administration was safe and may spur faster recovery of neutrophils and platelets than GM-CSF alone. Median time to a

Read the full 450 word article

How to gain access

Continue reading with a
two-week free trial.